Bengaluru company unveils cancer atlas mapping genomic diversity to bridge data gap
A private firm in Bengaluru unveiled a Global Cancer Diversity Atlas (GCDA) on May 14 with the aim of addressing the genomics data gap in cancer care.
The atlas was launched by Infosys co-founder N. R. Narayan Murthy. The initiative is aimed at addressing a critical gap in global cancer research — the lack of genomic data from diverse populations.
While most cancer genomic datasets are dominated by Western populations, the GCDA designed by 4baseCare, a precision oncology company, is built on real-world data from India and the global South.
While over 70% of cancer patients live in Asia, West Asia and Latin America, less than 10% of current cancer genomic data represents them. GCDA aims to bridge this disparity to ensure all populations are accurately represented in precision oncology.
The company claims that GCDA is the most inclusive cancer genomics dataset, transforming how it develops diagnostics, conducts research, and delivers cancer care.
By integrating region-specific genomic insights, GCDA empowers clinicians with tools for more accurate diagnosis and targeted treatments, helping to eliminate misdiagnoses and enhance outcomes for patients worldwide.
Mr. Murthy also launched the company's genomics lab in Mahadevapura. The lab will offer advanced genomic testing solutions, including comprehensive gene panels, whole exome sequencing and transcriptome analysis.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
a day ago
- India Today
Irritable Bowel Disease is now an epidemic: Why India is seeing a surge
A silent yet formidable health challenge is gaining ground across India: Inflammatory Bowel Disease (IBD).Once seldom encountered in clinical practice, this chronic condition of the gastrointestinal tract, that includes ulcerative colitis and Crohn's disease, is now surfacing with greater frequency in both metropolitan and smaller urban diagnoses rise and medical practitioners face mounting complexities in treatment and detection, IBD is emerging as a public health concern demanding urgent WHAT IS IBD? Irritable Bowel Disease (IBD) is a long-term condition that causes swelling and pain in the digestive are two types of IBD: Crohn's disease (inflammation in any part of the digestive tract) and ulcerative colitis (inflammation and ulcers in the colon and rectum).People with IBD often have stomach pain, diarrhea, tiredness, and weight loss. It's different from IBS and needs medical care to manage symptoms and RISE IN IBD IN INDIAA global study by researchers from the University of Chicago suggested that IBD is rising not just in the Western countries, but it is now infiltrating developing countries like India, even though a large population is vegetarian. People with IBD often have stomach pain, diarrhea, tiredness, and weight loss. It's different from IBS and needs medical care to manage symptoms and flare-ups. () advertisement"As a chronic inflammatory condition that is driven by immune system responses, IBD has been linked to so-called Western diets that are high in processed foods, animal products, and sugar while also low in fruits, vegetables, and whole grains. People in industrialising economies tend to adopt more elements of this diet, but that alone doesn't tell the full story. IBD is increasing in India, for example, which has a high proportion of people who are vegetarian," the researchers wrote in the peer-reviewed journal epidemiological projections paint an alarming picture: by 2035, India could be home to over two million IBD patients, a fourfold increase in less than two attribute this exponential rise to a confluence of environmental, dietary, and lifestyle changes, underscoring the intersection between modernity and the gut microbiome (micro-organisms in the digestive tract).A 2023 Lancet study by the IBD Centre at the Asian Institute of Gastroenterology (AIG), Hyderabad, underscores the gravity of the trend. According to the findings, the prevalence of IBD in the region surged from a modest 0.1% in 2006 to over 5% by 2022, a staggering escalation that reflects broader national patterns. Doctors attribute this exponential rise to a confluence of environmental, dietary, and lifestyle changes, underscoring the intersection between modernity and the gut microbiome. () "India is witnessing a rapid increase in IBD cases due to a transition from traditional Indian diets rich in fibre and natural foods to a more Westernised intake of processed foods, saturated fats, and sugars. This dietary shift has altered gut microbiota weakening intestinal barriers and potentially triggering the inflammation," explained Dr. Sharad Malhotra, senior consultant & director of gastroenterology at Aakash ANTIBIOTIC USEAmong the key factors that causes the development of IBD is early antibiotic exposure. Mounting evidence suggests that disruption of the gut microbiota during critical developmental stages may have long-lasting consequences."Antibiotic exposure during early childhood can disrupt the developing gut microbiota, leading to long-term alterations in microbial composition and function. This dysbiosis has been linked to an increased risk of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, later in life," noted Dr. Sunil Rana, associate director and head of internal medicine, Asian OF IBDThe diagnostic landscape in India presents its own unique challenges. IBD's symptomatic presentation, often including abdominal discomfort, chronic diarrhea, and unexplained weight loss, closely mimics that of other prevalent gastrointestinal conditions, particularly intestinal overlap has historically led to misdiagnoses with serious clinical implications. Antibiotic exposure during early childhood can disrupt the developing gut microbiota. () "The histopathological distinction between IBD or Crohn's and intestinal tuberculosis remains a critical challenge in India. Accurate biopsy analysis is essential because misdiagnosis can lead to inappropriate therapy and serious complications. Such patients may be subjected to ineffective treatments, delaying appropriate management and increasing morbidity," says Dr. Suhas Udgirkar, consultant of gastroenterology at Jupiter OF IBDClinicians are calling for a multidisciplinary approach to address these diagnostic difficulties."Many patients present with non-specific symptoms, making early detection difficult. A multidisciplinary approach is necessary, integrating clinical evaluation with detailed investigations to manage IBD effectively," added Dr. the barriers are not merely biological or infrastructural. Accurate diagnosis often relies on a combination of physical examinations, laboratory work, and endoscopic procedures, resources frequently unavailable in rural or non-specialist settings. Clinicians are calling for a multidisciplinary approach to address these diagnostic difficulties. () advertisement"The symptoms of IBD overlap with Irritable Bowel Syndrome. This does delay diagnosis. Individuals with alarming symptoms such as bleeding and severe abdominal pain need a complete evaluation. However, there is no single diagnostic test for Ulcerative Colitis or Crohn's Disease," explained Dr. Aakaar Kapoor, CEO of City XRay and Scan the issue is the social stigma surrounding chronic illness, particularly one that affects bowel health. The result: a culture of silence that delays care and exacerbates patient India grapples with the mounting burden of IBD, experts agree that timely diagnosis, access to advanced diagnostics, and de-stigmatising the disease are essential to slowing its Watch
&w=3840&q=100)
India.com
2 days ago
- India.com
Study Finds Genetic Variant That Doubles Dementia Risk In Men: What You Need To Know
New Delhi: Australian researchers have identified a common genetic variant that doubles the risk of dementia in men. The team from Curtin University said that one in three people carry one copy of the variant, known as H63D, while one in 36 carry two copies. The research, published in the journal Neurology, found that men who carry a double H63D variant are twice as likely to develop dementia in their lifetime compared to women. The study, based on 19,114 healthy older people in Australia and the US, investigated whether people who had variants in the hemochromatosis (HFE) gene, which is critical for regulating iron levels in the body, might be at increased risk of dementia. "Having just one copy of this gene variant does not impact someone's health or increase their risk of dementia. However, having two copies of the variant more than doubled the risk of dementia in men, but not women," said Professor John Olynyk, from the Curtin Medical School. "While the genetic variant itself cannot be changed, the brain pathways which it affects -- leading to the damage that causes dementia -- could potentially be treated if we understood more about it," Olynyk added. Professor Olynyk said further research was needed to investigate why this genetic variant increased the risk of dementia for males but not females. "The HFE gene is routinely tested for in most Western countries, including Australia, when assessing people for hemochromatosis -- a disorder that causes the body to absorb too much iron. Our findings suggest that perhaps this testing could be offered to men more broadly," Olynyk said. While the HFE gene is critical for controlling iron levels in the body, the team found no direct link between iron levels in the blood and increased dementia risk in affected men. "This points to other mechanisms at play, possibly involving the increased risk of brain injury from inflammation and cell damage in the body," Olynyk said. The findings could help improve outcomes for people at risk of developing dementia and pave the way for more personalised approaches to prevention and treatment, especially for men with the double H63D variant.
Hans India
2 days ago
- Hans India
Study finds common gene variant that doubles dementia risk for men
Australian researchers have identified a common genetic variant that doubles the risk of dementia in men. The team from Curtin University said that one in three people carry one copy of the variant, known as H63D, while one in 36 carry two copies. The research, published in the journal Neurology, found that men who carry a double H63D variant are twice as likely to develop dementia in their lifetime compared to women. The study, based on 19,114 healthy older people in Australia and the US, investigated whether people who had variants in the hemochromatosis (HFE) gene, which is critical for regulating iron levels in the body, might be at increased risk of dementia. "Having just one copy of this gene variant does not impact someone's health or increase their risk of dementia. However, having two copies of the variant more than doubled the risk of dementia in men, but not women," said Professor John Olynyk, from the Curtin Medical School. "While the genetic variant itself cannot be changed, the brain pathways which it affects -- leading to the damage that causes dementia -- could potentially be treated if we understood more about it," Olynyk added. Professor Olynyk said further research was needed to investigate why this genetic variant increased the risk of dementia for males but not females. "The HFE gene is routinely tested for in most Western countries, including Australia, when assessing people for hemochromatosis -- a disorder that causes the body to absorb too much iron. Our findings suggest that perhaps this testing could be offered to men more broadly," Olynyk said. While the HFE gene is critical for controlling iron levels in the body, the team found no direct link between iron levels in the blood and increased dementia risk in affected men. "This points to other mechanisms at play, possibly involving the increased risk of brain injury from inflammation and cell damage in the body," Olynyk said. The findings could help improve outcomes for people at risk of developing dementia and pave the way for more personalised approaches to prevention and treatment, especially for men with the double H63D variant.
